BioAffinity Technologies: Martin Tammemägi

BioAffinity Technologies announced Martin Tammemägi will become chairman of the company's scientific and medical advisory board. He was a co-investigator and remains active in the US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, the US National Lung Screening Trial, and the Pan-Canadian Early Detection of Lung Cancer Study. He is an active associate member of the US National Institutes of Health National Cancer Institute Cancer Intervention and Surveillance Modeling Network lung group and is the provincial scientific lead for Ontario Health - Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk.